NexPlasmaGen

NexPlasmaGen is a Canadian-based company that specializes in developing noninvasive plasma technologies to combat cancer. Founded in 2008, the company's mission revolves around reducing breast cancer recurrence rates and improving patients' survival rates at various stages of the disease. Their innovative plasma technology has shown promise in preclinical trials and is positioned as safe, efficient, versatile, and portable. In addition to enhancing patient outcomes, NexPlasmaGen aims to curtail the financial burden associated with cancer recurrence for both hospitals and patients. As of now, the company is preparing for safety clinical trials slated for 2023. With a focus on the Health and Wellness and Medical Devices sectors, NexPlasmaGen is poised to make significant strides in the fight against cancer.